A5070524913- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer, Hypoxia, and Metabolism
- RNA modifications and cancer
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Cancer Research and Treatments
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Lung Cancer Treatments and Mutations
- Organ Transplantation Techniques and Outcomes
- Liver Disease Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Gallbladder and Bile Duct Disorders
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Cancer Cells and Metastasis
- Radiomics and Machine Learning in Medical Imaging
KU Leuven
2015-2025
Universitair Ziekenhuis Leuven
2019-2024
VIB-KU Leuven Center for Cancer Biology
2024
Universitat de Vic - Universitat Central de Catalunya
2023
Centre Hospitalier Universitaire de Grenoble
2022
Austral University
2022
Paris-Est Sup
2022
Université Paris-Est Créteil
2022
Assistance Publique – Hôpitaux de Paris
2022
Hospital Universitario Austral
2022
Patients with metastatic colorectal cancer the BRAF V600E mutation have a poor prognosis, median overall survival of 4 to 6 months after failure initial therapy. Inhibition alone has limited activity because pathway reactivation through epidermal growth factor receptor signaling.
The positive BEACON colorectal cancer (CRC) safety lead-in, evaluating encorafenib + cetuximab binimetinib in previously treated patients with
Tumour budding, described as the presence of single cells or small clusters up to five tumour at invasive margin, is established a prognostic marker in colorectal carcinoma. In present study, we aimed investigate molecular signature budding and corresponding bulk. bulk areas were microdissected processed for RNA-sequencing. As little RNA was obtained from cells, special low-input mRNA library preparation protocol used. Gene expression profiles compared with investigated EMT signatures,...
Abstract Background Overcoming therapeutic resistance is one of the major hurdles in cancer care. One mechanism contributing to a process which epithelial cells switch mesenchymal state (epithelial-to-mesenchymal transition or EMT). The precise mechanisms driving EMT-mediated have, however, not been elucidated. Results Here, we study ten cell line pairs, for parental lines were made resistant either targeted chemotherapy-based treatment. First, show by miRNA-200 overexpression that treatment...
<sup>18</sup>F-labeled somatostatin analogs (SSAs) could represent a valid alternative to the current gold standard, <sup>68</sup>Ga-labeled SSAs, for receptor imaging in patients with neuroendocrine tumors (NETs), given their logistic advantages. Recently, <sup>18</sup>F-AlF-NOTA-octreotide (<sup>18</sup>F-AlF-OC) has emerged as promising candidate, but thorough comparison <sup>68</sup>Ga-DOTA-SSA large patient groups is needed. This prospective, multicenter trial aims demonstrate...
The combination of atezolizumab plus bevacizumab (atezo/bev) has dramatically changed the treatment landscape advanced HCC (aHCC), achieving durable responses in some patients. Using single-cell transcriptomics, we characterize intra-tumoural and peripheral immune context patients with aHCC treated atezo/bev. Tumours from are enriched for PDL1+ CXCL10+ macrophages and, based on cell-cell interaction analysis, express high levels CXCL9/10/11 predicted to attract CXCR3+ CD8+ effector-memory T...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a very lethal disease that can develop therapy resistance over time. The dense stroma in PDAC plays critical role tumor progression and resistance. How this interacts with the cells how influenced by chemotherapy remain poorly understood. METHODS: backbone of study parallel transcriptome analysis human mouse two molecular clinical representative patient-derived xenografts models. Mice (8 animals per group) were treated for 4 weeks...
Abstract Lynch syndrome (LS) and constitutional mismatch repair deficiency (CMMRD) are distinct cancer syndromes caused, respectively, by mono- bi-allelic germline (MMR) variants. LS predisposes to mainly gastrointestinal genitourinary cancers in adulthood. CMMRD brain, haematological, LS-spectrum from childhood. Two suspected patients with first diagnosis aged 27 or 38 years were found be homozygous for an MMR (likely) pathogenic variant, MSH6 c.3226C>T (p.(Arg1076Cys)), variant of...
Background and Aims: The outcome of patients with HCC who achieved complete response (CR) to immune-checkpoint inhibitor (ICI)–based systemic therapies is unclear. Approach Results: Retrospective study had CR according modified Response Evaluation Criteria in Solid Tumors (CR-mRECIST) ICI-based from 28 centers Asia, Europe, the United States. Of 3933 treated noncurative therapies, 174 (4.4%) CR-mRECIST, 97 (2.5%) RECISTv1.1 (CR-RECISTv1.1) as well. mean age total cohort (male, 85%;...
Epithelial-to-mesenchymal transition (EMT) is linked to tumor invasion, drug resistance and aggressive disease this largely dependent on the cell's microenvironment. Acriflavine (ACF) an old antibacterial recently also suggested as anticancer agent HIF inhibitor. We wanted study effect of acriflavine EMT in different human cancer models. Pancreatic cells (Panc-1) were exposed TGF-β1 or cobalt chloride (to mimick severe hypoxia) induce EMT. For our third model we HepG2 liver sorafenib which...
74 Background: CYAD-101 is a first-in-class, non-gene edited allogeneic CAR T-cell product that combines the broad breadth of tumor targeting NKG2D-based chimeric antigen receptor (CAR) with peptide-based approach controls graft versus host disease (GvHD). NKG2D binds eight ligands commonly over-expressed across many tumors while co-expressed (TCR) inhibitory (TIM) peptide interferes signaling by endogenous TCR. A bank cells was produced from single donor and evaluated in AlloSHRINK phase 1...
Fluorine-18-labeled SSAs have the potential to become next-generation tracer in SSTR-imaging neuroendocrine tumor (NET) patients given their logistical advantages over current gold standard gallium-68-labeled SSAs. In particular, [18F]AlF-OC has already shown excellent clinical performance. We demonstrated our previous report from prospective multicenter trial that PET/CT outperforms [68Ga]Ga-DOTA-SSA, but histological confirmation was lacking due ethical and practical reasons. this second...